AVCN Stock Overview
A commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for consumer, medical, and pharmaceutical markets worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Avicanna Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.40 |
| 52 Week High | CA$0.60 |
| 52 Week Low | CA$0.20 |
| Beta | 1.54 |
| 11 Month Change | 63.27% |
| 3 Month Change | -23.08% |
| 1 Year Change | 29.03% |
| 33 Year Change | -62.96% |
| 5 Year Change | n/a |
| Change since IPO | -93.58% |
Recent News & Updates
Shareholder Returns
| AVCN | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | 50.9% | -0.8% | 1.4% |
| 1Y | 29.0% | 33.2% | 8.4% |
Return vs Industry: AVCN underperformed the Canadian Pharmaceuticals industry which returned 44% over the past year.
Return vs Market: AVCN exceeded the Canadian Market which returned 9.9% over the past year.
Price Volatility
| AVCN volatility | |
|---|---|
| AVCN Average Weekly Movement | 14.9% |
| Pharmaceuticals Industry Average Movement | 13.1% |
| Market Average Movement | 8.2% |
| 10% most volatile stocks in CA Market | 16.7% |
| 10% least volatile stocks in CA Market | 3.0% |
Stable Share Price: AVCN's share price has been volatile over the past 3 months.
Volatility Over Time: AVCN's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Canadian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 87 | Aras Azadian | www.avicanna.com |
Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for consumer, medical, and pharmaceutical markets worldwide. It commercializes approximately thirty proprietary evidence-based finished products. The company provides medical cannabis formulary products, including oral, sublingual, topical, and transdermal deliveries with various ratios of cannabinoids under the RHO Phyto brand; and indication-specific pharmaceutical products to address unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders, such as Trunerox, an adjuvant treatment for seizures associated with Lennox-Gastaut Syndrome and Dravet Syndrome.
Avicanna Inc. Fundamentals Summary
| AVCN fundamental statistics | |
|---|---|
| Market cap | CA$39.17m |
| Earnings (TTM) | -CA$7.25m |
| Revenue (TTM) | CA$22.07m |
1.8x
P/S Ratio-5.4x
P/E RatioIs AVCN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AVCN income statement (TTM) | |
|---|---|
| Revenue | CA$22.07m |
| Cost of Revenue | CA$13.00m |
| Gross Profit | CA$9.07m |
| Other Expenses | CA$16.32m |
| Earnings | -CA$7.25m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.074 |
| Gross Margin | 41.09% |
| Net Profit Margin | -32.86% |
| Debt/Equity Ratio | 19.8% |
How did AVCN perform over the long term?
See historical performance and comparison